A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

This is a first in human dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of AND019 in postmenopausal women with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 \[HER2\]-negative) breast cancer.

Trial Details

NCT ID
NCT05187832
Phase
PHASE1
Sponsor
Kind Pharmaceuticals LLC
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • AND019 PO QD
Locations (sample)
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Postmenopausal women defined as NCCN guideline at the time of informed consent.
  • Histological or cytological confirmation of advanced or metastatic ER+/HER2- breast cancer women who failed standard therapy or for which no standa…
  • Prior therapy:
  • No more than 1 line of chemotherapy for advanced breast cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →